Fecal Calprotectin, Gut Inflammation and Spondyloarthritis.

[1]  Baoan Chen,et al.  Influence of diet and dietary nanoparticles on gut dysbiosis. , 2018, Microbial pathogenesis.

[2]  D. Ramón,et al.  Gut microbial composition in patients with psoriasis , 2018, Scientific Reports.

[3]  Wen-Ming Wang,et al.  Skin Microbiome: An Actor in the Pathogenesis of Psoriasis , 2018, Chinese medical journal.

[4]  H. Glerup,et al.  Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis , 2018, Scandinavian journal of rheumatology.

[5]  E. Soriano,et al.  Enthesitis: from pathophysiology to treatment , 2017, Nature Reviews Rheumatology.

[6]  S. Tahan,et al.  Fecal microbiota analysis of children with small intestinal bacterial overgrowth among residents of an urban slum in Brazil. , 2017, Jornal de pediatria.

[7]  L. Dubuquoy,et al.  Chronic bowel inflammation and inflammatory joint disease: Pathophysiology. , 2017, Joint, bone, spine : revue du rhumatisme.

[8]  R. Maizels,et al.  Helminths in the gastrointestinal tract as modulators of immunity and pathology , 2017, American journal of physiology. Gastrointestinal and liver physiology.

[9]  L. Öhman,et al.  A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis , 2017, Arthritis Research & Therapy.

[10]  K. Aalto,et al.  Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use , 2017, Pediatric Rheumatology.

[11]  T. Korn,et al.  Interleukin‐23–Dependent γ/δ T Cells Produce Interleukin‐17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice , 2016, Arthritis & rheumatology.

[12]  C. Miceli-Richard.  Enthesitis: The clue to the pathogenesis of spondyloarthritis? , 2015, Joint, bone, spine : revue du rhumatisme.

[13]  M. Benegas,et al.  Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America , 2012, The Journal of Rheumatology.

[14]  S. Targan,et al.  Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study , 2012, Arthritis Research & Therapy.

[15]  T. Mcclanahan,et al.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells , 2012, Nature Medicine.

[16]  N. Kennedy,et al.  The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease , 2012, The American Journal of Gastroenterology.

[17]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis , 2009, Annals of the rheumatic diseases.

[18]  M. Färkkilä,et al.  Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings , 2008, Alimentary pharmacology & therapeutics.

[19]  M. Dougados,et al.  Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[20]  C. Araujo,et al.  Helminth products as a potential therapeutic strategy for inflammatory diseases. , 2008, Inflammation & Allergy - Drug Targets.

[21]  M. Färkkilä,et al.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.

[22]  L. Denson,et al.  Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[23]  M. Neurath,et al.  Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. , 2003, The Journal of clinical investigation.

[24]  M. Dougados,et al.  Assessment of enthesitis in ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[25]  S P McKenna,et al.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[26]  T. Lyberg,et al.  Functional and clinical aspects of the myelomonocyte protein calprotectin. , 1997, Molecular pathology : MP.

[27]  P. Tugwell,et al.  Crosscultural reliability of the physical ability dimension of the health assessment questionnaire. , 1990, The Journal of rheumatology.

[28]  P. Sampaio-Barros,et al.  Different ethnic background is associated with distinct clinical profiles in the spondyloarthritides in the North and South of Brazil , 2018, Clinical Rheumatology.

[29]  M. M. Moreno Ramos,et al.  Relationship between fecal calprotectin, anti-Saccharomyces cerevisiae antibodies and other markers of disease activity in patients with spondyloarthritis. , 2018, Reumatologia clinica.

[30]  M. Orman,et al.  Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. , 2016, Bosnian journal of basic medical sciences.

[31]  R. Nisihara,et al.  FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. , 2015, Arquivos de gastroenterologia.

[32]  S. Shinjo,et al.  Brazilian-Portuguese version and applicability questionnaire of the mobility index for ankylosing spondyliti. , 2007, Clinics.